Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Summit Therapeutics ( (SMMT) ).
On May 30, 2025, Summit Therapeutics announced positive topline results from its Phase III HARMONi clinical trial, which evaluated ivonescimab in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer. The trial demonstrated a statistically significant improvement in progression-free survival and a positive trend in overall survival, suggesting potential benefits for patients in regions including North America and China. These results may influence Summit’s decision on the timing of a Biologics License Application filing with the FDA, as the agency requires a statistically significant overall survival benefit for marketing authorization.
The most recent analyst rating on (SMMT) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.
Spark’s Take on SMMT Stock
According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.
Summit Therapeutics’ stock score reflects significant financial challenges, including lack of revenue and ongoing losses, balanced by a strong equity position. Technical indicators show positive momentum, supporting short-term interest. Valuation remains weak due to negative earnings and no dividend. Positive clinical developments from the earnings call bolster the score, highlighting potential for future growth.
To see Spark’s full report on SMMT stock, click here.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is primarily engaged in the clinical development of ivonescimab, a novel bispecific antibody designed to treat non-small cell lung cancer (NSCLC) and other solid tumors.
Average Trading Volume: 3,939,205
Technical Sentiment Signal: Buy
Current Market Cap: $19.34B
Find detailed analytics on SMMT stock on TipRanks’ Stock Analysis page.